Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | ENPP2 | Q13822 | 11/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.52 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17966877 | 0.85 | TP53 (0.62) | LMNAENPP2TP53TBXA2RMAPT | |
| SCHEMBL7095165 | 0.84 | LMNA (0.54) | LMNAENPP2TP53TBXA2RAGTR1 | |
| SCHEMBL15244777 | 0.78 | LMNA (0.66) | LMNAENPP2TP53TBXA2RMEN1 | |
| SCHEMBL7823224 | 0.76 | LMNA (0.46) | LMNAENPP2TP53TBXA2RMEN1 | |
| SCHEMBL9853648 | 0.76 | PPARG (0.74) | AGTR1AGTR2 | |
| SCHEMBL15071581 | 0.75 | BRD4 (0.51) | LMNAENPP2TP53TBXA2RAGTR1 | |
| SCHEMBL9760633 | 0.75 | LMNA (0.61) | LMNAENPP2TP53MEN1KMT2A | |
| SCHEMBL7851373 | 0.74 | AGTR1 (0.75) | AGTR1AGTR2 | |
| SCHEMBL8566073 | 0.73 | PPARG (0.61) | LMNAENPP2TP53TBXA2RAGTR1 | |
| SCHEMBL9761791 | 0.73 | LMNA (0.59) | LMNAENPP2TP53TBXA2RMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0676398-B1 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO CO (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-6117893-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 2000-09-12 | — | — | US | disclosed |
| EP-1022274-A1 | Oxazolidinedione and Thiazolidinedione derivatves, their preparation and their use | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
| US-5977365-A | HYPOGLYCEMIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5962470-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5834501-A | TREATING DIABETES OR HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5739345-A | HYPOGLYCEMIC AND ANTIDIABETIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |